European Medicines Agency (EMA) tells NeuroSearch a European license for Huntexil in HD requires another large trial
How can we improve recruitment into Huntington's disease clinical trials? Talking directly with families works!
Dimebon fails to improve symptoms in HD patients in the HORIZON trial
Bad news for Huntexil – the FDA requires another trial before it can be approved in the US
Success for brain ‘gene therapy’ in Parkinson’s disease – good news for similar treatments being developed in HD
Dimebon – disappointing results in an Alzheimer’s disease trial, but hope remains for HD.
Two clinical trials in Europe and the USA have suggested a new drug, Huntexil, might improve movements in HD. The nex
DOMINO clinical trial result: minocycline doesn’t slow down HD and shouldn’t be studied in larger trials.